SCHOTT Pharma AG & Co. KGaA Share Price
Equities
1SXP
DE000A3ENQ51
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.09 EUR | +0.47% |
|
-2.33% | -0.26% |
| 06:19pm | SCHOTT PHARMA : Jefferies reiterates its Neutral rating | ZD |
| 15/01 | SCHOTT PHARMA : Jefferies gives a Neutral rating | ZD |
| Capitalization | 226.22Cr 262.62Cr 210.82Cr 196.13Cr 364.88Cr 24TCr 391.41Cr 2.42TCr 953.16Cr 11TCr 984.78Cr 964.64Cr 42TCr | P/E ratio 2026 * |
15.8x | P/E ratio 2027 * | 13.3x |
|---|---|---|---|---|---|
| Enterprise value | 242.12Cr 281.08Cr 225.64Cr 209.92Cr 390.52Cr 25TCr 418.92Cr 2.59TCr 1.02TCr 12TCr 1.05TCr 1.03TCr 45TCr | EV / Sales 2026 * |
2.41x | EV / Sales 2027 * | 2.13x |
| Free-Float |
23% | Yield 2026 * |
1.06% | Yield 2027 * | 1.24% |
Last Transcript: SCHOTT Pharma AG & Co. KGaA
| 1 day | +0.47% | ||
| 1 week | -2.33% | ||
| Current month | -0.26% | ||
| 1 month | +1.07% | ||
| 3 months | -24.70% | ||
| 6 months | -42.63% | ||
| Current year | -0.26% |
| 1 week | 14.88 |  | 15.8 |
| 1 month | 14.56 | | 15.8 |
| Current year | 14.64 | | 15.8 |
| 1 year | 14.56 | | 30.25 |
| 3 years | 14.56 | | 43.4 |
| 5 years | 14.56 | | 43.4 |
| 10 years | 14.56 | | 43.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andreas Reisse
CEO | Chief Executive Officer | 65 | 01/07/2022 |
Reinhard Mayer
DFI | Director of Finance/CFO | 58 | 01/08/2025 |
Tobias Erfurth
IRC | Investor Relations Contact | - | 30/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 04/04/2023 | |
Wolfgang Wienand
BRD | Director/Board Member | 54 | 04/04/2023 |
| Director/Board Member | 51 | 04/04/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.47% | -2.33% | -38.28% | - | 262.62Cr | |
| -1.18% | -2.10% | +11.19% | +8.83% | 21TCr | |
| +0.26% | +0.31% | +15.93% | +22.84% | 13TCr | |
| +1.55% | +5.84% | +49.51% | +116.31% | 6.89TCr | |
| +0.45% | +1.54% | -10.42% | -18.57% | 5.94TCr | |
| -1.11% | +1.34% | +24.63% | +93.17% | 5.47TCr | |
| -1.61% | +3.54% | - | - | 3.55TCr | |
| -0.66% | +1.18% | -13.88% | -36.17% | 2.7TCr | |
| +1.52% | +2.91% | +29.81% | +32.78% | 2.63TCr | |
| +1.04% | +0.28% | +8.29% | -33.49% | 2.4TCr | |
| Average | +0.28% | +0.99% | +8.53% | +23.21% | 6.4TCr | |
| Weighted average by Cap. | +0.14% | +0.54% | +15.01% | +26.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100.52Cr 116.7Cr 94Cr 87Cr 162.14Cr 11TCr 173.93Cr 1.08TCr 423.55Cr 5.04TCr 437.6Cr 428.65Cr 18TCr | 108.65Cr 126.13Cr 101.25Cr 94Cr 175.24Cr 11TCr 187.98Cr 1.16TCr 457.77Cr 5.45TCr 472.96Cr 463.29Cr 20TCr |
| Net income | 15Cr 17Cr 14Cr 13Cr 23Cr 1.52TCr 25Cr 155.43Cr 61Cr 727.87Cr 63Cr 62Cr 2.67TCr | 17Cr 19Cr 16Cr 14Cr 27Cr 1.75TCr 29Cr 178.64Cr 70Cr 836.58Cr 73Cr 71Cr 3.07TCr |
| Net Debt | 16Cr 18Cr 15Cr 14Cr 26Cr 1.67TCr 28Cr 170.25Cr 67Cr 797.29Cr 69Cr 68Cr 2.92TCr | 5.25Cr 6.09Cr 4.89Cr 4.55Cr 8.47Cr 550.67Cr 9.08Cr 56Cr 22Cr 263.26Cr 23Cr 22Cr 965.77Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | 15.06 € | +0.27% | 15,463 |
| 15/26/15 | 15.02 € | -0.53% | 86,741 |
| 14/26/14 | 15.10 € | -1.56% | 83,834 |
| 13/26/13 | 15.34 € | -1.67% | 1,12,026 |
| 12/26/12 | 15.60 € | +1.17% | 69,865 |
Delayed Quote Xetra, January 16, 2026 at 05:32 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1SXP Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition